Clinical Trials Directory

Trials / Completed

CompletedNCT04871776

Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
3,671 (actual)
Sponsor
Brigham and Women's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.

Conditions

Interventions

TypeNameDescription
BEHAVIORALMessaging informed by construal level theoryMessages are informed by construal level theory, which suggests that emphasizing "why" elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing "how" is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake.
BEHAVIORALUsual CareUsual messaging sent by Mass General Brigham

Timeline

Start date
2022-02-18
Primary completion
2022-05-27
Completion
2022-08-17
First posted
2021-05-04
Last updated
2024-01-16
Results posted
2024-01-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04871776. Inclusion in this directory is not an endorsement.